Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
G. Jerusalem*, G. Mariani, E. M. Ciruelos, M. Martin, V. C. G. Tjan-Heijnen, P. Neven, J. G. Gavila, A. Michelotti, F. Montemurro, D. Generali, E. Simoncini, I. Lang, J. Mardiak, B. Naume, M. Camozzi, K. Lorizzo, S. Bianchetti, P. Conte
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)'. Together they form a unique fingerprint.